Pancreatic Cancer Research

ResearcherTottori UniversityActive in the last 2 years

Takehiko Hanaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4008-0207; OpenAlex author ID A5054915917. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 4 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers

Papers 18

  1. The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. Co-author DOI 10.1007/s00595-024-02877-z↗
  2. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… Co-author DOI 10.1016/j.hpb.2024.03.603↗
  3. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… Co-author DOI 10.1097/md.0000000000038292↗
  4. TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2022.101608↗
  5. High Glucose-stimulated aPKC Activation Promotes Pancreatic Cancer Cell Progression Through YAP Signaling. Co-author DOI 10.21873/anticanres.16681↗
  6. Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer. Co-author DOI 10.33160/yam.2023.05.014↗
  7. Modified geriatric nutritional risk index in patients with pancreatic cancer: a propensity score-matched analysis. Co-author DOI 10.1186/s12885-022-10071-y↗
  8. Geriatric nutritional risk index as a prognostic factor in patients with recurrent pancreatic cancer. Co-author DOI 10.1371/journal.pone.0271073↗
  9. Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Co-author DOI 10.1038/s41598-021-94711-6↗
  10. The prognostic significance of combined geriatric nutritional risk index and psoas muscle volume in older patients with pancreatic cancer. Co-author DOI 10.1186/s12885-021-08094-y↗
  11. Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1186/s12893-020-00976-5↗
  12. Cytoplasmic-only Expression of Maspin Predicts Unfavorable Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15032↗
  13. Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.11.028↗
  14. Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study. Co-author DOI 10.1186/s12957-020-01981-x↗
  15. Prognostic Impact of Pre- and Post-operative P-CRP Levels in Pancreatic Cancer Patients. Co-author DOI 10.33160/yam.2020.02.011↗
  16. C-Reactive Protein/Albumin Ratio and Prognostic Nutritional Index Are Strong Prognostic Indicators of Survival in Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1089/crpc.2017.0006↗
  17. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00595-016-1308-6↗
  18. Nicotine enhances the malignant potential of human pancreatic cancer cells via activation of atypical protein kinase C. Co-author DOI 10.1016/j.bbagen.2016.07.008↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teruhisa Sakamoto · 17 shared papers, 2016–2024 · strength 2.38
  2. Yoshiyuki Fujiwara · 14 shared papers, 2020–2024 · strength 2.07
  3. Yuki Murakami · 6 shared papers, 2021–2024 · strength 1.03
  4. Masaki Morimoto · 7 shared papers, 2020–2023 · strength 0.88
  5. Teppei Sunaguchi · 4 shared papers, 2022–2023 · strength 0.61
  6. Mikiya Kishino · 3 shared papers, 2024 · strength 0.60
  7. Ei Uchinaka · 5 shared papers, 2020–2021 · strength 0.59
  8. Takuki Yagyu · 5 shared papers, 2020–2021 · strength 0.57
  9. Tatsuya Matsura · 4 shared papers, 2016–2023 · strength 0.50
  10. Joji Watanabe · 3 shared papers, 2016–2021 · strength 0.28
  11. Yoshihisa Umekita · 2 shared papers, 2020–2021 · strength 0.25
  12. Yoshiyuki Fujiwara · 1 shared paper, 2024 · strength 0.20
  13. Masahide Ikeguchi · 3 shared papers, 2016–2017 · strength 0.19
  14. Kazushi Hara · 1 shared paper, 2023 · strength 0.17
  15. Hiroyuki Kugoh · 1 shared paper, 2021 · strength 0.12
  16. Masataka Amisaki · 2 shared papers, 2016 · strength 0.11
  17. Seiichi Nakamura · 1 shared paper, 2017 · strength 0.08
  18. Tetsu Shimizu · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.